Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

2 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Week 3 - 13 and 25 - Laboratory Results; Physical Examination; Post-Treatment Response

- 30/03/2021 - 1 Formulário, 19 Grupos de itens, 62 Elementos de dados, 1 Idioma
Grupos de itens: Administrative, Laboratory Results (Week 3-13, 25) - Hematology, Laboratory Results (Week 3-13, 25) - Hematology, Laboratory Results (Week 25) - Hematology , Laboratory Results (Week 3, 13, 25) - Chemistry, Laboratory Results (Week 3 and 13) - Chemistry, Laboratory Results (Week 7) - Chemistry, Laboratory Results (Week 7) - Chemistry , Laboratory Results (Week 25) - Chemistry , Physical Examination (Week 7, 13, 25), Physical Examination (Week 7, 13, 25), Post-Treatment Response (Week 7, 13, 25) - CT or other Radiological Imaging Results, Post-Treatment Response (Week 7, 13, 25) - Bone Marrow Biopsy, Post-Treatment Response (Week 7 and 13) - Received medication/transfusion, Post-Treatment Response (Week 7, 13, 25) - Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Week 7, 13, 25) - Response, Signature of Investigator
Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Cisplatin and Topotecan Recurrent on Persistent Carcinoma of the Cervix - 103369 - Drug Dose Form

- 14/03/2019 - 1 Formulário, 6 Grupos de itens, 38 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Investigational Product, Drug Dose, Tumor Measurements, Best Tumor Response, Pre-treatment Hematologies and Chemistries
Study ID: 103369 Clinical Study ID: 103369 Study Title: A Randomized Phase III Study of Cisplatin Versus Cisplatin plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: Topotecan Study Indication: Cancer 

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial